



Oregon Drug Use Review / Pharmacy & Therapeutics Committee

Thursday, August 6th, 2026

1:05 PM - 4:45 PM

Via Zoom webinar

MEETING MINUTES

NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence, and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee, and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 in accordance with Oregon Revised Statute 183.333

Members Present: Stacy Ramirez, PharmD; Patrick DeMartino, MD; Jennifer Henderson, DO; Russ Huffman, PMHNP; Bruce Leewiwatanakul, DO; Eriko Onishi, MD; Eddie Saito, PharmD

Staff Present: Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Andrew Gibler, PharmD; Deanna Moretz, PharmD; Kathy Sentena, PharmD; Sarah Servid, PharmD; Lan Starkweather, PharmD; Brandon Wells; Dee Weston; Trevor Douglass, DC; Lewis Backus; Michael Yu

Audience: Pieter Muntendam*, SQ Innovation; Joseph Galanto*, Sanofi; Kristy Heppner*, Denali Therapeutics; Amy Yang*, MD, OHSU; Christine Dube*, Astrazeneca; Audra Johnson*, Genentech; Rick Kegler*, BioMarin; Sergio Gomez, Concis Labs; Miranda Ryzenman, Artia Solutions; Shoua Liu; Lori Howarth, Bayer; Tammi Ocumpaugh, Novo Nordisk; Jill Carroll, Bristol Myers Squibb; Jess Boucher, Takeda; Lindsay Buck, Biogen; Jessica Osborn, OSU Student; Rilee Sechrist, Moda EOCCO; Bryan Armstrong, CareOregon; Liz Breitenstein, OHA; Michael Foster, Ultragenyx; Dale Fisher; Melissa Snider, Gilead; Gary Parenteau, Dexcom; Chris Johnson, BioMarin; Ashlee Waring, Organon; Shauna Wick; Becky Caswell, OHSU Health; Kenneth Orr; Hassan Muhammad, Abbott; Mark Kantor, AllCare; Gloria Zepeda, AllCare; Aliethia McLeod, Trillium; Lisa Pulver; JJ Roth; Cody Traweek; Mike Donabedian, Sarepta Therapeutics; Raya Nematian; Andrea Silva; Lindsay Buck, Biogen; Adam Furman; Lynda Finch, Biogen; Jenny Todenhagen; Shoua Liu; Rilee Sechrist, Moda EOCCO

(*) Provided verbal testimony

I. CALL TO ORDER

- A. Roll Call & Introductions
 - Meeting called to order at approx. 1:05 p.m., introductions by Committee and staff
 - B. Conflict of Interest Declaration – no new conflicts of interest were declared
 - C. Approval of Agenda and June Minutes presented by Roger Citron, RPh
- ACTION: Motion to approve, 2nd, all in favor**



- D. Department Update and recognition of Stacy Ramirez who will be stepping down from the Committee, provided by Trevor Douglass, DC, MPH
- E. Election of Vice-Chair as Dr. Stevens will become Chair with Dr. Ramirez's departure
Dr. Saito volunteered to serve as Vice-Chair
ACTION: Motion to approve, 2nd, all in favor
- F. Mental Health Clinical Advisory Group (MHCAG) Update presented by Andrew Gibler, PharmD

II. CONSENT AGENDA TOPICS

- A. **Quarterly Utilization Report**
- B. **Oncology Prior Authorization (PA) Updates**
Recommendation:
 - Add: CAVHANZA (Nilotinib); DECNUPAZ (pivekimab sunirine-pvzy); BEQALZI (sonrotoclax); and VEPPANU (vepdegestrant) to Table 1 in the Oncology Agents PA criteria
- C. **Non-Insulin Diabetes Drugs Literature Scan**
Recommendation:
 - No changes to the PDL are recommended based on the review of the clinical evidence
 - Remove PA for preferred SGLT-2 Inhibitors and update approved indications in Table 1 of PA criteria
 - Evaluate costs in executive session
- D. **Glaucoma Drugs Literature Scan**
Recommendation:
 - No changes to the PDL are recommended based on the review of the clinical evidence
 - Evaluate costs in executive session
- E. **Antianginals Literature Scan**
Recommendation:
 - No changes to the PDL are recommended based on the review of the clinical evidence
 - Evaluate costs in executive session
- F. **Ophthalmic Anti-inflammatory Drugs Lit Scan**
 - No changes to the PDL are recommended based on the review of the clinical evidence
 - Maintain BYQLOVI (clobetasol) 0.05%, LOTEMAX SM (loteprednol) 0.38%, and INVELTY (loteprednol) 1% ophthalmic preparations as non-preferred
 - Evaluate costs in executive session
- G. **Topical Steroids Literature Scan**
 - No changes to the PDL are recommended based on the review of the clinical evidence
 - Evaluate costs in executive session
- H. **Combination Antihypertensive Drugs, Calcium Channel Blockers and Oral Beta-Blockers Lit Scan**
Recommendation:
 - Maintain LOPRESSOR (metoprolol) oral solution, SDALMO (amlodipine) oral powder, WIDAPLIK (telmisartan/amlodipine/indapamide) tablets, NORLIQVA (amlodipine) oral solution, CONJPRI (levamlodipine) tablets, KATERZIA (amlodipine) oral solution, and BYVALSON (nebivolol/valsartan) tablets as non-preferred
 - No changes to the PDL are recommended based on the review of the clinical evidence
 - Evaluate costs in executive session
- I. **Oral Potassium and Potassium Phosphate Literature Scan**
 - No changes to the PDL are recommended based on the review of the clinical evidence



Drug Use Research & Management Program

OHA Health Systems Division

500 Summer Street NE, E35; Salem, OR 97301-1079

College of Pharmacy Phone 503-947-5220 | Fax 503-947-1119

- Evaluate costs in executive session

ACTION: Motion to approve, 2nd, all in favor

III. DRUG USE REVIEW (DUR) ACTIVITIES

- A. **ProDUR Report:** presented by Lan Starkweather, PharmD
- B. **RetroDUR Report:** presented by Dave Engen, PharmD
- C. **Oregon State Drug Review:** presented Kathy Sentena, PharmD
 - 1. **Update on Targeted Immune Modulators Used to Manage Selected Autoimmune Conditions**
 - 2. **Chronic Kidney Disease Pharmacotherapy: Guideline Updates & Practical Application**
 - 3. **Eating Disorders and Disordered Eating Behaviors in Patients with Diabetes**

IV. OLD BUSINESS

- A. **Healthier Oregon Policy Update: Antifungals, Oral:** Sarah Servid, PharmD

Recommendation:

- Evaluate costs in executive session

ACTION: Motion to approve, 2nd, all in favor

V. NEW BUSINESS

- A. **Redemplo (plozasiran) New Drug Evaluation:** Megan Herink, PharmD

Recommendation:

- Make plozasiran non-preferred in the “Other Dyslipidemia Drug” PDL class

- Include plozasiran in the **Apolipoprotein C-III Inhibitors** PA criteria to ensure it is used according to supporting evidence and FDA labeling

ACTION: Motion to approve, 2nd, all in favor

- B. **Newer Drugs for Heart Failure Class Update:** Deanna Moretz, PharmD

Recommendation:

- Rename “Diuretics, Oral” to “Diuretics, Outpatient” to include new outpatient sub-Q and nasal formulations

- Update **Finerenone** PA criteria to include use in patients with LVEF > 40%

- Maintain the following as non-preferred on the PDL: chlorthalidone 12.5 mg tabs; sub-Q forms of furosemide; oral suspensions and solutions of HCTZ, losartan, and ramipril; and bumetanide nasal spray

- Make a metolazone product preferred based upon AHA recommendation

- Retire **Sacubitril/Valsartan (Entresto)** PA to support the use of ARNIs as part of GDMT in heart failure

- Evaluate drug costs in executive session

Public Comment: Pieter Muntendam, SQ Innovation, Inc

ACTION: Motion to approve, 2nd, all in favor



Drug Use Research & Management Program

OHA Health Systems Division

500 Summer Street NE, E35; Salem, OR 97301-1079

College of Pharmacy Phone 503-947-5220 | Fax 503-947-1119

C. Tzield (teplizumab) Prior Authorization Update: Kathy Sentena, PharmD

Recommendations:

- No changes to the PDL are recommended based on the review of clinical evidence
- Maintain teplizumab as non-preferred
- Update **Teplizumab** PA criteria to include the new indication for teplizumab for use in Stage 3 T1D

Public Comment: Joseph Galanto, Sanofi

ACTION: Modify proposed PA criteria Q#3 to ask “Does the patient have Stage 3 T1D and/or” has the patient previously been treated with teplizumab

Motion to approve, 2nd, all in favor

D. Herpes Simplex Class Update: Kathy Sentena, PharmD

Recommendations:

- No changes to the PDL are recommended based on the review of clinical evidence
- Update **Antivirals for Herpes Simplex Virus** PA criteria to accommodate future changes to the prioritized list of health services
- Evaluate drug costs in the executive session

ACTION: Motion to approve, 2nd, all in favor

E. Enzyme Replacement for Hunter Syndrome Orphan Drug Evaluations: Deanna Moretz, PharmD

Recommendations:

- Create a PDL class of drugs for “MPS II (Hunter syndrome)”
- Implement **Enzyme Replacement Therapy for Hunter Syndrome** PA criteria for the use of idursulfase and tividrenofusp alfa-eknm, based on the FDA approved indications in patients with MPS II

Public Comment: Kristy Heppner, Denali Therapeutics; Dr. Amy Yang, OHSU

ACTION: Modify: Q#5 to allow switching therapies; Q#9 change to neurocognitive “decline” to “deficit”; Q#10 add an echocardiogram and/or sleep study to document baseline disease severity; and Q#12 add “or does the genotype predict a neurologic form of Hunter syndrome (examples: gene truncation or deletion; prior case report or family member with the same gene variant showing neurologic Hunter syndrome)?”

Motion to approve, 2nd, all in favor

F. Monoclonal Antibodies for Lupus Class Update and New Drug Evaluation: Sara Fletcher, PharmD

Recommendations:

- Move Gazyva (obinutuzumab) to “Monoclonal Antibodies for Lupus” Class and implement **Obinutuzumab (GAZYVA)** PA with a clear pathway to the **Oncology Agents** policy for oncology indications and make non-preferred
- Update **Anifrolumab-fnia** and **Belimumab (Benlysta)** PA criteria as presented to allow longer approval duration

Public Comment: Christine Dube, Astrazeneca; Audra Johnson, Genentech

ACTION: Drop Q#10 UPCR (urine protein to creatine ratio) to 0.5 mg/mg

Motion to approve, 2nd, all in favor



Drug Use Research & Management Program

OHA Health Systems Division

500 Summer Street NE, E35; Salem, OR 97301-1079

College of Pharmacy Phone 503-947-5220 | Fax 503-947-1119

G. C-Type Natriuretic Peptides Class Update and New Drug Evaluation: Deanna Moretz, PharmD

Recommendations:

- Add the "C-Type Natriuretic Peptides" class to the PDL and include vosoritide and navepegritide
- Designate vosoritide and navepegritide non-preferred
- Implement the proposed **C-type Natriuretic Peptides** PA criteria to ensure appropriate use

ACTION: Motion to approve, 2nd, all in favor

VI. EXECUTIVE SESSION

Members Present: Stacy Ramirez, PharmD; Patrick DeMartino, MD; Jennifer Henderson, DO; Russ Huffman, PMHNP; Bruce Leewiwatanakul, DO; Eriko Onishi, MD

Staff Present: Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Andrew Gibler, PharmD; Deanna Moretz, PharmD; Kathy Sentena, PharmD; Sarah Servid, PharmD; Lan Starkweather, PharmD; Lewis Backus; Michael Yu

VII. RECONVENE for PUBLIC RECOMMENDATIONS

A. Non-Insulin Diabetes Drugs Literature Scan

Recommendation:

- **DPP-4 Inhibitors:** Make linagliptin/metformin, alogliptin and alogliptin/metformin preferred; and Onglyza non-preferred
- **Misc. Diabetes Drugs:** Make repaglinide, acarbose, metformin ER osmotic, glipizide-metformin, nateglinide, glyburide-metformin, and metformin ER gastric preferred
- **SGLT-2 Inhibitors:** Make Jardiance non-preferred
- **Sulfonylureas:** Make chlorpropamide, glipizide tablets, glipizide ER 24 tablets, and micronized glyburide preferred

ACTION: Motion to approve, 2nd, all in favor

B. Glaucoma Drugs Literature Scan

Recommendation:

- Make dorzolamide drops, brimonidine 0.2% drops, and the beta blockers levobunolol and timolol maleate-PF preferred

ACTION: Motion to approve, 2nd, all in favor

C. Antianginals Literature Scan

Recommendations:

- Make isosorbide mononitrate ER, isosorbide dinitrate SL tabs and ranolazine tab ER 12h preferred
- Make isosorbide mononitrate IR tablets non-preferred

ACTION: Motion to approve, 2nd, all in favor



Drug Use Research & Management Program

OHA Health Systems Division

500 Summer Street NE, E35; Salem, OR 97301-1079

College of Pharmacy Phone 503-947-5220 | Fax 503-947-1119

D. Ophthalmic Anti-inflammatory Drugs Literature Scan

Recommendations:

- Make difluprednate drops and prednisolone sodium phosphate drops preferred

ACTION: Motion to approve, 2nd, all in favor

E. Topical Steroids Literature Scan

Recommendations:

- Make all generic hydrocortisone rectal products, hydrocortisone-aloe cream, clobetasol shampoo, emollient cream, gel and foam, hydrocortisone lotion, fluticasone cream and ointment, desonide lotion, betamethasone valerate lotion, betamethasone ointment and foam, betamethasone pg ointment, triamcinolone lotion, halobetasol ointment and cream, fluocinolone solution, gel, oil, and ointment, fluocinolone shower cap oil, fluocinonide ointment and gel, and mometasone cream, ointment and solution preferred
- Make hydrocortisone gel, fluocinonide-dimethicone kit, and clobetasol 0.025% cream non-preferred

ACTION: Motion to approve, 2nd, all in favor

F. Combination Antihypertensive Drugs, Calcium Channel Blockers and Oral Beta-Blockers Lit Scan

Recommendations:

- **Beta-blockers:** Make sotalol, nebivolol and bisoprolol preferred
- **Calcium Channel Blockers:** Make felodipine, diltiazem 24-hour ER (LA), nifedipine capsules, and generic nimodipine capsules preferred. Make NIMOTOP capsules and nimodipine solution non-preferred
- **Combination Antihypertensives:** Make valsartan-HCTZ, amlodipine-benazepril, irbesartan-HCTZ, bisoprolol-HCTZ, atenolol-chlorthalidone, amlodipine-valsartan, and candesartan-HCTZ preferred

ACTION: Motion to approve, 2nd, all in favor

G. Oral Potassium and Potassium Phosphate Literature Scan

Recommendations:

- Make Kaochlor liquid, potassium gluconate elixir, KCL ER capsules and tablets, Effer-K packets, Klor-Con packets, and K-Vesent packets preferred
- Make Pokonza products non-preferred

ACTION: Motion to approve, 2nd, all in favor

H. HOP Policy Update: Oral Antifungals

Recommendations:

- Make ketoconazole tablets and itraconazole capsules preferred

ACTION: Motion to approve, 2nd, all in favor

I. Newer Drugs for Heart Failure Class Update

Recommendations:

- Make the diuretics eplerenone and metolazone preferred
- Make the RAAS inhibitors captopril and perindopril preferred
- Make the ARNI sacubitril/valsartan preferred



Drug Use Research & Management Program

OHA Health Systems Division

500 Summer Street NE, E35; Salem, OR 97301-1079

College of Pharmacy Phone 503-947-5220 | Fax 503-947-1119

- Make valsartan solution non-preferred

ACTION: Motion to approve, 2nd, all in favor

J. Herpes Simplex Class Update

Recommendations:

- Make famciclovir tablets preferred

ACTION: Motion to approve, 2nd, all in favor

VIII. ADJOURN